RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
Thromb Haemost 2002; 88(04): 700-701
DOI: 10.1055/s-0037-1613285
DOI: 10.1055/s-0037-1613285
Letters to the Editor
Is the Poor Recovery of Commercial Recombinant Factors VIII and IX caused by Damage from Monoclonal Antibody Purification?
Weitere Informationen
Publikationsverlauf
Received
24. Mai 2002
Accepted
28. Mai 2002
Publikationsdatum:
09. Dezember 2017 (online)
-
References
- 1 Stollar BD. Proteolytic antibodies against factor VIII in Hemophilia A. [Editorial]. N Engl J Med 2002; 346: 702-3.
- 2 Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Villard S, Pashov A, Stieltjes N, d’Oiron R, Saint-Remy J-M, Hoebeke J, Kazatchkine MD, Kaveri SV. The prevalence of proteolytic antibodies against factor VIII in Hemophilia A. N Engl J Med 2002; 346: 662-7.
- 3 Foster PA, Fulcher CA, Houghten RA, de Graaf SMahoney, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 1988; 82: 123-8.